Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis

Table 1 Characteristics of included studies

Ref.	Year	Country	Male/All sex	Positive males	Positive females	Median age	Grade I+II/III+IV	Positive I+II/III+IV	Method	HR and 95%CI	HR and 95%CI source	Cut-off	Follow-up time in months	NOS score
Batista et al[15]	2016	Spain	79/152	13	58	-	0+77/75+0	0+12/16+0	IHC	0.98 (0.84-1.15)	Reported	-	50	7
Schäfer et al[16]	2018	Germany	282/471	268	183	50.6	0+111/141+219	0+106/137+208	IHC	2.37 (1.37-4.01)	Reported	10	-	6
Behling et al[17]	2020	Germany	67/113	-	-	64	0/0+113	0/0+89	IHC	1.16 (0.66-2.03)	K-M curve	10	37	7
Zhong et al[18]	2020	China	167/277	60	60	51	0/0+277	0/0+216	IHC	0.66 (0.46-0.94)	K-M curve	10	60	6
Zhou et al[19]	2023	China	49/73	29	13	49.95	0/0+73	0/0+42	IHC	0.11 (0.05-0.65)	K-M curve	30	30	6
Mei et al[20]	2023	China	78/119	-	-	51.1	0/0+119	0/0+74	IHC	0.49 (0.28-0.82)	K-M curve	10	60	7

HR: Hazard ratio; IHC: Immunohistochemistry; K-M: Kaplan-Meier; NOS: Newcastle Ottawa Score.

Table 2 Subgroup analysis of the relationships between oligodendrocyte transcription factor 2 expression and overall survival

Comparison variables	Number of studies	Number of people	HR and 95%CI	P value	Heterogeneity by I2 statistics
Total	6	1205	0.81 (0.51-1.27)	0.000	84.5
Country
Europe	3	736	1.34 (0.79-2.27)	0.008	79.3
Asian	3	469	0.43 (0.22-0.84)	0.027	72.3
number
> 150	3	900	1.10 (0.65-1.86)	0.001	86.7
≤ 50	3	305	0.46 (0.17-1.29)	0.002	84.0
Median age
> 50	4	980	0.96 (0.50-1.84)	0.000	85.8
≤ 50	1	73	0.11 (0.03-0.40)	-	-
No referred	1	152	0.98 (0.84-1.15)	-	-
WHO grade
II-III	2	404	1.47 (0.62-3.47)	0.002	89.6
IV	4	801	0.72 (0.36-1.45)	0.000	87.0
Method
Reported	2	623	1.47 (0.62-3.47)	0.002	89.6
K-M curve	4	582	0.56 (0.31-1.01)	0.006	76.0
Cut-off
> 10	1	73	0.11 (0.03-0.40)	0.000	85.8
≤ 10	4	980	0.96 (0.50-1.84)	-	-
Follow up time
> 50	2	396	0.60 (0.45-0.81)	0.366	0.0
≤ 50	3	338	0.67 (0.31-1.46)	0.003	82.6

HR: Hazard ratio; K-M: Kaplan-Meier; WHO: World Health Organization.